KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses (2016 - 2026)

Acadia Pharmaceuticals has reported Other Accumulated Expenses over the past 15 years, most recently at $5.6 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 64.81% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, up 64.81%, while the annual FY2025 figure was $5.6 million, 64.81% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $5.6 million at Acadia Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $13.7 million in Q1 2024 and troughed at $986000.0 in Q2 2022.
  • A 5-year average of $6.3 million and a median of $5.3 million in 2025 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 777.84% in 2023 and later plummeted 69.31% in 2024.
  • Year by year, Other Accumulated Expenses stood at $2.7 million in 2021, then rose by 0.82% to $2.7 million in 2022, then soared by 307.53% to $11.0 million in 2023, then plummeted by 69.31% to $3.4 million in 2024, then skyrocketed by 64.81% to $5.6 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ACAD at $5.6 million in Q4 2025, $5.0 million in Q3 2025, and $13.4 million in Q2 2025.